06 Sep 2017

N+1 Singer - Morning Song 06-09-2017

Xaar plc (XAR:LON), 121 | Itaconix plc (ITX:LON), 108 | Severfield Plc (SFR:LON), 30.2 | Summit Therapeutics Inc (SMMT:NAS), 0 | ReNeuron Group plc (RNUGF:OTC), 0 | Synairgen plc (SYGGF:OTC), 0

- Singer CM Team
- 15 pages

Itaconix (ITX LN) Agreement with AkzoNobel to develop bio-based chelates | Itaconix (ITX LN) Agreement with AkzoNobel to develop bio-based chelates | Severfield (SFR LN) In line AGM statement | Summit Therapeutics (SUMM LN) Exploratory data supports ridinilazole’s selectivity | Synairgen (SNG LN) Lead LOXL2 compound on track to commence Phase I in Q4 2017 | Vectura Group (VEC LN) H1 results in line, but flutiform® destocking a concern for H2 | Xaar (XAR LN) Interim results in line; transformatio ....

Sign up to access

Get access to our full offering from over 30 providers

Get access to our full offering from over 30 providers

N+1 Singer - Morning Song 06-09-2017

Xaar plc (XAR:LON), 121 | Itaconix plc (ITX:LON), 108 | Severfield Plc (SFR:LON), 30.2 | Summit Therapeutics Inc (SMMT:NAS), 0 | ReNeuron Group plc (RNUGF:OTC), 0 | Synairgen plc (SYGGF:OTC), 0

Published: 06 Sep 2017
Author: Singer CM Team
Pages: 15

Itaconix (ITX LN) Agreement with AkzoNobel to develop bio-based chelates | Itaconix (ITX LN) Agreement with AkzoNobel to develop bio-based chelates | Severfield (SFR LN) In line AGM statement | Summit Therapeutics (SUMM LN) Exploratory data supports ridinilazole’s selectivity | Synairgen (SNG LN) Lead LOXL2 compound on track to commence Phase I in Q4 2017 | Vectura Group (VEC LN) H1 results in line, but flutiform® destocking a concern for H2 | Xaar (XAR LN) Interim results in line; transformatio ....

Top